NEW YORK (GenomeWeb News) – Mizuho Securities today upgraded shares of Myriad Genetics to a Buy rating, citing an increase in Medicare reimbursements for the BRACAnalysis test, as well as stabilized competition, and several potential positive catalysts over the next year to 24 months.

Analyst Peter Lawson upgraded the company's stock from a prior Neutral rating and raised his 12-month price target on Myriad's shares to $50 from $40.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.